Nyxoah Appoints Rita Johnson-Mills to its Board of Directors Mont-Saint-Guibert, Belgium – August 27, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today
Taiwan’s Ministry of Labor (MOL) has announced new rules aimed at limiting migrant workers’ ability to transfer to new jobs across different sectors despite criticism that the policy ignores conditions that are driving the trend.The new restrictions, w…
Taiwan on Saturday recorded six new imported cases of COVID-19 but no new domestic transmissions for the second straight day and no deaths from the disease, according to the Central Epidemic Command Center (CECC).At a press briefing, however, Health an…
A total of 30,000 doses of the Moderna COVID-19 vaccine donated by the Czech Republic are expected to arrive at Taiwan Taoyuan International Airport on Sunday, according to the airport.The Moderna doses will be flown in on a Turkish Airlines passenger …
For the third consecutive year, the Gartner report recognizes Epicor for its vision and execution Austin, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) — Epicor Software Corporation, a global provider of industry-specific enterprise software to promote business growth, has been named a Visionary in the 2021 Gartner Magic Quadrant for Cloud ERP for
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002 NEW YORK, Friday August 27, 2021 – ImmunoBrain Checkpoint Inc. (“IBC”) an innovative biopharmaceutical company developing potential disease-modifying immune therapies that harness the power of the immune system to help protect and
SHANGHAI, China, Aug. 27, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted an investigational new drug application for UBP1213sc, its
